Wound Care Biologics Market Size, Share & Industry Analysis, By Product Type (Skin Substitute {Biological [Allografts, Xenografts, and Others], and Synthetic}, and Topical Agents), By Wound Type (Chronic Wounds {Diabetic Foot Ulcers (DFU), Venous Leg Ulcers, and Others}, and Acute Wounds {Burns, Surgical & Traumatic Wounds, and Others}), By End-user (Hospitals & ASCs, Clinics, and Others), and Regional Forecast, 2026-2034

The global wound care biologics market is experiencing significant growth due to the shift from conventional wound care to biologics, including growth factors such as cell-based therapies, and bioengineered skin substitutes. This shift is primarily due to enhanced tissue regeneration, reduced healing time, and a lower risk of amputation compared to traditional wound care.

Moreover, the increasing research and development for wound care biologics is expected to introduce new products, thereby contributing to market expansion.

Wound Care Biologics Market Driver

Increasing Incidence of Chronic and Acute Wounds to Fuel Growth

Over recent years, the rising incidence of chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, has increased the number of patients seeking treatment, particularly in emerging markets and countries with high diabetes rates. Additionally, recent clinical data have shown improved healing rates with wound care biologics in complex wounds, such as diabetic foot ulcers and burns. This is expected to increase its adoption, driving the market growth in the upcoming years.

• For instance, a November 2023 study published in the Journal of the American Medical Association projected that diabetic foot ulcers affect around 18.6 million individuals globally each year, including approximately 1.6 million in the U.S.

Download Free sample to learn more about this report.

As reported by Onenessbio in May 2025, approximately 13.0% of adults with diabetes in North America were affected by diabetic foot ulcers (DFU).

Wound Care Biologics Market Restraint

Lower Diagnosis and Treatment Rates to Hinder the Market Growth

Despite multiple organizational efforts to improve wound management, the delayed diagnosis of chronic wounds continues to be prevalent. Factors such as late referrals and limited clinical expertise in identifying diabetic foot ulcers in emergency settings are leading to delayed treatment.

• For instance, a 2023 study in the Diabetic Foot Journal highlighted that, for patients with diabetes suffering from chronic limb-threatening ischemia or foot ulceration, the median delay from symptom onset to specialist evaluation ranged between 15 and 126 days, while the initiation of treatment occurred 1 to 91 days after assessment.

These diagnostic inefficiencies are highly observed in emerging economies such as India, China, and Brazil, where constrained healthcare infrastructure, limited public awareness, and uneven access to specialized care lead to delays in treatments and limit the adoption of advanced wound care biologics.

Wound Care Biologics Market Opportunity

Integration of Biologics with Advanced Digital Wound Care Platforms to Offer Lucrative Growth Opportunities

In recent years, the combination of biologic therapies with digital wound monitoring and telehealth systems is expected to offer a significant opportunity for wound management globally. Integrating sensors, mobile imaging, and AI analytics has enabled clinicians to track biologic response rates and customize treatment regimens in real time. This convergence has improved healing outcomes in chronic wounds, aligning with the shift toward personalized regenerative medicine and remote care delivery models.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Diseases, By Key Countries/ Region, 2024
• Advancements in Wound Care Biologics
• Key Industry Developments - (Mergers, Acquisitions & Partnerships, and Others)
• Pricing Analysis, Key Players, 2024

Analysis by Product Type

Based on product type, the market is subdivided into skin substitute {biological [allografts, xenografts, and others], and synthetic}, and topical agents.

The skin substitutes segment is expected to account for the largest market share during the forecast period. The segment’s growth is attributed to the increasing preference for biological skin substitutes due to their dual regenerative and protective functions. Moreover, the demand for wound care biologics is higher in developed regions, where chronic wound prevalence and reimbursement support are more prevalent.

Analysis by Wound Type

The market, by wound type, is categorized into chronic wounds {Diabetic Foot Ulcers (DFU), venous leg ulcers, and others}, and acute wounds {burns, surgical & traumatic wounds, and others}.

The chronic wounds segment is expected to hold a major share during the forecast period. The growth is primarily driven by the rising global burden of diabetic foot ulcers, which represents a significant patient population in need of effective wound management solutions. The presence of well-defined clinical guidelines and favorable reimbursement frameworks in key regions is further supporting the adoption of active therapies, including wound care biologics, for the treatment of chronic wounds.

• For instance, according to data published by Elsevier B.V. in February 2022, diabetic foot ulcers affect about 6.3% of the global population.

Analysis by End-user

By end-user, the market is subdivided into hospitals & ASCs, clinics, and others.

The hospitals & ASCs segment held the largest market share in 2024. The greater adoption of wound care biologics in hospital settings is driven by the rising number of chronic wound cases managed within these facilities and the availability of supportive reimbursement policies in major markets. Additionally, increased government expenditure on wound treatment in hospitals is expected to further accelerate the adoption of biologic-based therapies, significantly contributing to the segment’s overall growth.

• For instance, in April 2023, the National Health Service (NHS) in England allocated around USD 10.32 billion to wound care, ranking it as the third-highest healthcare expenditure category following cancer and diabetes.

Regional Analysis

Request for Customization   to gain extensive market insights.

The market has been studied across North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa based on region.

North America held the largest global market share for wound care biologics in 2024. The growth is attributed to higher per capita healthcare spending, which is supporting the adoption of advanced wound care biologics in the region. In addition, increasing partnerships between key players and hospitals & ASCs are improving product availability and strengthening market penetration of such products in the region.

The Asia Pacific region is projected to register the fastest growth rate over the forecast period. This expansion is mainly due to the region’s large diabetic population, which is increasing the prevalence of chronic wounds such as diabetic foot ulcers and creating strong demand for effective treatment options. Consequently, physicians are increasingly recommending wound care biologics for improved healing outcomes, which is expected to further drive regional market growth in the forthcoming years.

• For instance, data from the International Diabetes Federation indicated that in 2024, China recorded approximately 147.98 million adult diabetes cases.

Key Players Covered

The global wound care biologics market is fragmented, with key players holding a major share. These companies have a strong geographic presence and are significantly increasing their investments in new technologies to compete efficiently in the market.

The report includes the profiles of the following key players:

• MIMEDX Group, Inc. (U.S.)
• Organogenesis Inc. (U.S.)
• Smith+Nephew (U.K.)
• Convatec (U.K.)
• Kerecis (Iceland)
• Mölnlycke Health Care AB (Sweden)
• Skye Biologics Holdings, LLC (U.S.)
• Life Biologics (U.S.)
• BioStem Technologies, Inc. (U.S.)

Key Industry Developments

• October 2024: BioLab Holdings, Inc. launched its Tri-Membrane Wrap, a robust triple-layered amniotic membrane skin substitute designed to protect deep and difficult-to-cover wounds.
• August 2023: Coloplast A/S acquired Kerecis, a biologics wound care company, strengthening its position in the U.S., Iceland, and Germany markets.